Serum Institute seeks DGCI nod for clinical trials of Covid vaccine Covavax

Serum Institute of India (SII), whose Covishield vaccine has already received restricted emergency use approval by the Drugs Controller General of India (DCGI), has now sought permission to start clinical trials of 'Covovax', a Covid-19 vaccine developed by Novavax.

Adar Poonawalla, CEO of SII, in a tweet said: "Our partnership for a Covid-19 vaccine with Novavax has also published excellent efficacy results. We have also applied to start trials in India. Hope to launch Covovax by June 2021."